References
- Bowers DG, Lynch JB. Adriamycin extravasation. Plast Reconst Surg 1978; 61: 86–92.
- Reilly JJ, Neifeld JP, Rosenberg SA. Clinical course and management of accidental Adriamycin extravasion. Cancer 1977; 40: 2053–2056.
- Rudolph R, Stein RS, Patillo RA. Skin ulcers due to Adriamycin. Cancer 1976; 38: 1087–1094.
- Dorr RT, Alberts RS, Chen HSG. Experimental model of Doxorubicin extravasation in the mouse. J Pharmacol Meth 1980; 4: 237–250.
- Rudolph R, Suzuki M, Luce JK. Experimental skin necrosis produced by Adriamycin. Cancer Treat Rep. 1979; 63: 529–537.
- Rudolph R, Woodward M, Hurn I. Ultrastructure of Doxorubicin (Adriamycin)-induced skin ulcers in rats. Cancer Res. 1979; 39: 3689–3693.
- Calendi E, Di Marco A, Reggiani M, Scarpinato B, Valentini L. On physico-chemical interactions between Daunomycin and nucleic acid. Biochim Biophys Acta 1965; 103: 25–49.
- Soble J, Dorr RT, Plezia P, Breckenridge S. Dose-dependent skin ulcers in mice treated with DNA binding antitumor antibiotics. Cancer Chemother Pharmacol 1987; 20: 33–36.
- Burke TG, Sartorelli AC, Tritton TR. Selectivity of the anthracyclines for negatively charged model membranes: role of amino group. Cancer Chemother Pharmacol. 1988; 21: 274–280.
- Goloman R, Facchinetti T, Bach D, Raz A, Sginitziki M. A differential interaction of Daunomycin, Adriamycin and their derivatives with human erythrocytes and phospholipid bilayers. Biochim Biophys Acta 1978; 512: 254–269.
- Schioppacassi G., Schwartz HS. Membrane actions of Daunorubicin in mammalian erythrocytes. Res Comm Pathol Pharmacol. 1977; 18: 519–524.
- Schwartz HS., Schioppacassi G, Kanter PM. Mechanisms of selectivity of intercalating agents. Antibiot Chemother 1978; 23: 247–257.
- Tritton TR, Yee G. The anticancer agent Adriamycin can be actively cytotoxic without entering cells. Science 1982; 217: 248–250.
- Barlock A, Howser D, Hubbar S. Nursing management of Adriamycin extravasation. Am J Nurs 1979; 79: 94-96.
- Daugherty JP, Khurana A. Amelioration of Doxorubicin-induced skin necrosis in mice by butylated hydroxytoluene. Cancer Chemother Pharmacol 1985; 14: 243–246.
- Desai MH, Teres D. Prevention of Doxorubicin-induced skin ulcers in the rat and pig with dimenthyl sulfoxide (DMSO). Cancer Treat Rep 1982; 66: 1371–1374.
- Dorr RT, Alberts DS. Failure of DMSO and Vitamin E to prevent Doxorubicin skin ulceration in the mouse. Cancer Treat Rep 1983; 67: 499–501.
- Ignoffo RJ, Friedman MA. Therapy of local toxicities caused by extravasation of cancer chemotherapeutic drugs. Cancer Treat Rep. 1980; 7: 17–27.
- Larson DL. Treatment of tissue extravasation by anti-tumor agents. Cancer 1982; 49: 1796–1799.
- Laughlin RS, Landeen JM, Habal MB. The management of inadvertent subcutaneous Adriamycin infiltration. Am J Surg 1979; 137: 408–410.
- Nobbs P, Barr RD. Soft tissue injury caused by antineoplastic drugs is inhibited by topical dimethyl-sulfoxide and alpha-tocopherol. Br J Cancer 1983; 48: 873–876.
- Olver IN, Schwarz MA. Use of dimethyl sulfoxide in limiting tissue damage caused by extravasation of Doxorubicin. Cancer Chemother Rep 1983; 67: 407–408.
- Svingen BA, Powis G, Appel PL, Scott M. Protection against Adriamycin-induced skin necrosis in the rat by dimethyl-sulfoxide and alpha-tocopherol. Cancer Res 1981; 41: 3395–3399.
- Jenkins J, Corden BJ. Vesicant activity of chemotherapeutic agents. Cancer Treat Rep. 1983; 67: 409.
- Barr RD, Benton SG, Belbeck LW. Soft tissue necrosis induced by extravasated cancer chemotherapeutic agents. J Natl Cancer Inst 1981; 66: 1129–1132.
- Garnik M, Israel M, Khetarpal V, Luce J. Persistence of anthracycline levels following dermal and subcutaneous Adriamycin extravasation. Proc AACR ASCO 1981; 22: 685.
- Heterington C. Olac manual. 2nd Ed. Pubi, by Olac 1976 Ltd. Bicester - U.K.